Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ainos, Inc. - warrants (NQ:AIMDW)

0.1401 -0.0050 (-3.45%)
Streaming Delayed Price Updated: 3:34 PM EDT, Oct 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ainos, Inc. - warrants

< Previous 1 2 3 4 Next >
Water Tower Research Highlights Ainos' Significant Commercial Traction and Strategic Milestones Across Multiple Sectors
Via ACCESS Newswire
Ainos Reports First Quarter 2025 Financial Results
Via ACCESS Newswire
Ainos Forms Partnership with ASE's Key Site to Power AI-Driven SmellTech in Semiconductor Smart Manufacturing
Via ACCESS Newswire
Water Tower Research Spotlights Ainos' Smell Integration in Humanoid Robot - AI Smelltech is Progressing Rapidly
Via ACCESS Newswire
Ainos and ugo Complete First Robotic Smell Integration in Japan
Via ACCESS Newswire
Ainos Secures TFDA Approval and IRB Clearance to Advance VELDONA Clinical Trials for HIV Oral Warts and Sjögren's Syndrome in Taiwan
Via ACCESS Newswire
Ainos and ASE Partner to Power AI Scent Digitization in Semiconductor Manufacturing
Via ACCESS Newswire
Ainos Reports Full Year 2024 Financial Results
Via ACCESS Newswire
Water Tower Research Highlights Ainos & ugo Partnership: The Final Sense for Robots - AI Smell is Here
Via ACCESS Newswire
Water Tower Research Highlights Ainos' AI Nose Expansion into Robotics and Semiconductor Manufacturing - Smell ID Is Scaling
Via ACCESS Newswire
Ainos to Participate in Fireside Chat with Water Tower Research on April 8, 2025
Via ACCESS Newswire
Water Tower Research Spotlights Ainos & ASE Partnership: Unleashing AI Nose’s Potential in Chip Manufacturing and More
Via ACCESS Newswire
Ainos Achieves Major Breakthrough: Japan Patent Approval for VELDONA Redefines Antiviral Innovation
Via ACCESS Newswire
Water Tower Research Spotlights Ainos' AI Nose Programs and Strategic Milestones for 2025
Via ACCESS Newswire
Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONA
Via ACCESSWIRE
Water Tower Research Highlights IRB Approval for the Ainos VELDONA Clinical Sjogren's Trial Alongside 3Q24 Earnings and Developments
Via ACCESSWIRE
Ainos Reports Third Quarter 2024 Financial Results
Via ACCESSWIRE
Ainos Expands Patent Portfolio With Strategic Shareholder’s Cutting-Edge Technology Assets
Via ACCESSWIRE
Ainos Granted 180-Day Extension by Nasdaq to Regain Compliance With Minimum Bid Price Rule
Via ACCESS Newswire
Ainos Unveils AI Nose for Robotics: Invites Global Robotics Companies to Join Forces in Shaping the Future of Smell-Enabled Robots
Via ACCESSWIRE
CORRECTION BY SOURCE: Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONA
Via ACCESSWIRE
Ainos Joins Webull Corporate Connect Service Platform to Enhance Investor Engagement
Via ACCESSWIRE
Water Tower Research Underscores Ainos' Partnership With Taiwan Tanabe Seiyaku for VELDONA Manufacturing and Marketing
Via ACCESSWIRE
Ainos Highlights VELDONA Clinical Advancements and Market Potential in Water Tower Research Spotlight Podcast
Via ACCESSWIRE
Ainos Spotlighted in Water Tower Research Report on VELDONA Clinical Study for Sjogren’s Syndrome
Via ACCESSWIRE
Ainos Announces IRB Approval for Sjögren’s Syndrome Clinical Study at Shuang Ho Hospital, Affiliated with Taipei Medical University, and Plans to Initiate New Phase of Treatment Evaluation in Q1 2025
Via ACCESSWIRE
Ainos Takes Decisive Action to Protect Stockholder Interests and Combat Potential Illegal Trading Activities
Via ACCESSWIRE
Ainos Advances Healthcare and Industrial Innovations with AI Nose and VELDONA Technologies
Via ACCESSWIRE
Ainos, Inc. Receives IRB Approval From National Taiwan University Hospital for HIV-Oral Warts Clinical Trial, Highlighting Value of FDA-Designated Orphan Drug VELDONA
Via ACCESSWIRE
Ainos Announced Plan to Initiate Taiwan Clinical Study of VELDONA for Treating Sjögren's Syndrome, a Rare Disease With Limited Treatment Options
Via ACCESSWIRE
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.